Professor Mallory Factor KCNG is the Founder, Chairman and CEO of IntraBio Inc. A serial entrepreneur, Professor Factor has successfully launched, developed and/or invested in numerous early-stage companies over his 30-year career, including two medical devices startups which resulted in an IPO and a successful trade sale, respectively. Professor Factor has had an extensive career in both the public and private sectors, including as the Founder and President of Mallory Factor Inc., which advises and invests in private and public biotechnology, technology, and manufacturing companies. He has served as a Member of the Board of Governors of the New York State Banking Department, the Chairman of The New York Public Asset Fund, and a Member (Presidential Appointee) of the Federal Home Loan Bank, Savings and Loan Council, and has testified extensively before Congress as an expert witness. He is a Life Member of the Council on Foreign Relations.
Professor Factor received his BA in Biochemistry from Wesleyan University and studied in the Joint Business and Law Program at Columbia University. Professor Factor is currently a Senior Visiting Fellow at the Department of Pharmacology at the University of Oxford, and is the John C. West Professor of International Politics and American Government at The Citadel in Charleston, South Carolina. Professor Factor is a celebrated author of two New York Times Best Selling books, has published dozens of articles, and is a frequent contributor to publications and media including The Wall Street Journal, Forbes Magazine, Sky News, FOXNews and the BBC.
Jim Meyers is the President and Chief Executive Officer of IntraBio Inc. He is an accomplished commercial leader and brings more than thirty years of experience within the biotechnology industry. Twenty-two of those thirty years were spent at Gilead Sciences, most recently serving as Executive Vice President of Worldwide Commercial Operations and Chief Commercial Officer, where he was responsible for the commercialization of all Gilead products, including pricing and market access, in North America, Europe, Middle East, Australia, and Japan.
During his time at Gilead, Mr. Meyers led some of the most important product launches in biopharmaceutical history, including 11 brands each with peak annual revenue of over $1billion and the two most successful launches in history as measured by first-year revenue: Harvoni & Sovaldi. Since February 2018, Mr, Meyers has served as a Senior Advisor to several different biopharmaceutical companies, including Gilead and the Boston Consulting Group. He serves on the Board of three publicly-traded biotech companies: Sangamo Therapeutics, CytomX Therapeutics, and Arbutus Biopharma. Mr. Meyers holds a B.S. in Economics from Boston College.
Taylor Fields is Senior Vice-President of IntraBio Inc. Prior to joining IntraBio, she obtained her master’s degree at the University of Oxford, where she investigated systems design and the processes by which behavioral change and cognitive evolution are engineered through the transformations of physical infrastructures and temporal-arrangements. At IntraBio, she leads all collaborative efforts related to the development and commercialization of IntraBio’s novel treatment and therapies.
Ms. Fields has an undergraduate degree in International Studies and English from the University of Michigan. She has diverse experience in both the public and private sector, having worked and consulted for non-profit and privately-held organizations out of the U.S, Europe, and Asia, specializing in communications and long-term strategic planning.
Dr. Ian Billington is the Chief Information Officer of IntraBio Inc. Dr. Billington brings nearly 25 years of experience in pharma consulting and finance, especially in the areas of structuring highly sophisticated instruments and using complex legal and corporate entities for risk mitigation, and is responsible for IntraBio’s overall intellectual property efforts and regulatory strategy. Prior to joining IntraBio, Mr. Billington was a Managing Director in the Fixed Income and Currencies division of UBS, where he spent 20 years working out of London, Tokyo and Hong Kong, responsible for both trading and risk managing structured products on a global basis, and overseeing quantitative research in that area. Before UBS, Dr. Billington began his career with ZS Associates, where he was a consultant to the pharmaceutical industry in the U.S. and Europe on topics of sales and customer demand creation.
Dr. Billington obtained a B.A. in Theoretical Physics from the University of Cambridge, and received a D. Phil. in Astrophysics from the University of Oxford.
Jason Brueschke is the Chief Financial Officer of IntraBio Inc. Mr. Brueschke has over 25 years of experience working in finance, law and start-up. Prior to joining IntraBio, he worked for nearly eight years as a senior equity analyst, beginning 2009 as Head of the Hong Kong Office before moving to the U.K. in 2013, at Discovery Capital Management, dual-strategy Macro + Equity Long/Short hedge fund during a period when AUM went from $4 billion to a peak of $16 billion. Prior to Discovery, Mr. Brueschke was a Managing Director and Head of the Pan-Asian Entertainment, Media and Telecoms (EMT) team at Citi Investment Research in Hong Kong, after having joined Citi in 2005 as Head of the Asian Internet & Media team, covering companies in China, India, Korea, Hong Kong and Singapore. With at Citi, Mr. Brueschke was consistently the top-ranked Asian Internet and Media analyst in the Institutional Investor and Greenwich investor polls. From 2002-2005, Mr. Brueschke worked in San Francisco at Pacific Growth Equities covering the US Software sector.
Mr. Brueschke started his research career in 2000 at Robertson Stephens in London where he was the Head of the European Software & IT Services team. Mr. Brueschke has an undergraduate degree in Biology from Princeton University, a JD with Highest Honors from the University of Oklahoma School of Law, and an MBA from the Stanford University Graduate School of Business. Before entering research, he co-founded a Business Process Outsourcing startup in San Francisco in 1997. He has previously worked as a lawyer at Fulbright & Jaworski, as Judicial Clerk for the Hon. E. Grady Jolly at the US Court of Appeals for the Fifth Circuit, and served as a Legal Advisor at the Iran-US Claims Tribunal at The Hague. From 2002 to 2011, he served on the Board of the International Business Ethics Institute in Washington, D.C.
Elizabeth Factor is the Chief Administrative Officer and Member of the Board of Directors of IntraBio Inc. As a former Director and Audit Committee Member for the United Nations Development Corporation, a Private Member of the New York State Financial Control Board, and as a Commissioner and Executive Committee Member of the South Carolina Arts Commission, Ms. Factor brings extensive experience in developing and implementing corporate and fiscal governance programs, as well as internal control guidelines, in a variety of corporate and government settings. Ms. Factor is also a former international tax lawyer at Cleary, Gottlieb, Steen & Hamilton, as well as at Babcock & Brown LP, and has over 20 years of experience in financial structuring and asset utilization. From 2003 to 2008, she was a Term Member on the Council on Foreign Relations.
Ms. Factor has an undergraduate degree in History from Columbia University and is a graduate of Yale Law School, where she was Executive Editor of Yale Journal on Regulation. Ms. Factor is also a published author and editor on a wide range of issues, including public policy, state and local government finance, and American politics.
Susan Flint is the Clinical Program Director at IntraBio. Ms. Flint has over 30 years of experience in global clinical operations and regulatory affairs. Prior to joining IntraBio, Ms. Flint was the Vice President and Head of Clinical Operations at Wilson Therapeutics AB, where she led the international clinical global development team conducting Phase 2 and Phase 3 clinical trials for orphan indications. Following the purchase of Wilson Therapeutics AB by Alexion, Ms. Flint led the clinical operations transition of two ongoing Phase 2 trials and one ongoing Phase 3 trials to Alexion.
Ms. Flint has extensive experience in clinical trials and regulatory affairs in the US, EU, and Canada, and has led several international Phase 1-3 clinical programs for pharmaceutical companies specializing in rare and orphan diseases, central nervous system, and oncology indications. She has successfully filed over 10 New Drug Applications/Marketing Approval Authorizations, more than 20 Investigational New Drug Applications, and 4 Orphan Drug Applications.
Ms. Flint has a Master of Science degree in pharmacology and a Bachelor of Science degree in biology. She is a member of the Regulatory Affairs Professional Society, the Association of Clinical Research Professionals, and the Drug Information Association.
Christa Verburg is the Senior Clinical Project Manager at IntraBio and has over 20 years of experiences in clinical operations and management.
Ms. Verburg started in the pharmaceutical industry in 1996 as an international CRA before working as a global project manager for small and medium-sized, and large and pharmaceutical companies. She has worked in all stages of clinical development, including serving as the Vice President Clinical Operations for a Phase 1, first-in-man conducting drug-drug interaction and full pharmacokinetic studies.
Ms. Verburg specializes in managing complex, pediatric Orphan Drug trials. At IntraBio, she is the principal manager for the ongoing IB1001 studies and oversees all CRAs and site management.
Ms. Verburg studied the Science of Human Movements at the University in Amsterdam.